epilepsy
EPILEPSY
Epilepsy is a clinical multiaxial diagnosis.
Epileptic seizure is a transient occurrence of signs/symptoms brought about by abnormal excessive or synchronous neuronal activity in the brain.
It is recommended that all patients having a first seizure be referred as soon as possible to a specialist to ensure accurate and early diagnosis and initiation of treatment appropriate to the needs of the patients.
Drug Information

Indication: Neuropathic pain in adults. Adjunctive therapy in adults w/ partial seizures w/ or w/o secondary generalisatio...

Indication: Adjunctive treatment of partial-onset seizures w/ or w/o secondarily generalized seizures in patients ≥12 y...

Indication: Adjunctive treatment of seizures associated w/ Lennox-Gaustaut syndrome in adults & childn ≥4 yr.

Indication: Adjunctive therapy in treatment of partial seizures w/ & w/o secondary generalization in adults & chil...

Indication: Monotherapy in patients w/ newly diagnosed epilepsy or for conversion to monotherapy in patients w/ epilepsy. ...

Indication: Monotherapy for partial seizures w/ or w/o secondary generalisation in adults w/ newly diagnosed epilepsy. Adj...

Indication: Anxiety, acute alcohol w/drawal symptoms, pre-op procedures to relieve anxiety & tension; adjunct prior to...

Indication: Control of generalised tonic-clonic (grand mal) epilepsy & psychomotor seizures.

Indication: Control of tonic-clonic (grand mal) status epilepticus & prevention & treatment of seizures occurring ...

Indication: Induction & maintenance of general anaesth, sedation of ventilated patients receiving intensive care &...

1  /  6
Editor's Recommendations
Most Read Articles
Audrey Abella, 15 Aug 2018
Supervised aerobic-strength training improved cognitive and motor functions among elderly individuals with mild cognitive impairment (MCI), according to studies presented at AAIC 2018.
12 May 2019
A consistent association exists between perinatal maternal depressive symptoms and child brain development assessed 10 years later, suggests a recent study.
02 Sep 2016
Results of a study show that patients with relapsing-remitting multiple sclerosis may benefit from the new sphingosine 1-phosphate 1 inhibitor drug amiselimod.